Future Medicine launches Neuropsychiatry

Future Medicine Ltd has today announced the launch of Neuropsychiatry – a new bimonthly title addressing all the latest trends in the field, from R&D through to clinical application and management, presenting research, findings, analysis and commentaries from experts around the world. Neuropsychiatry is published by Future Medicine Ltd (UK, London) renowned for its collection of journals providing healthcare practitioners and research professionals with a unique source of objective, cutting-edge information on exciting trends emerging in light of advances in medicine, healthcare and clinical practice.

Articles published in Neuropsychiatry cover a broad range of topics, from schizophrenia to anxiety disorders, Tourette’s syndrome, late-life depression, pathophysiology, cognitive behavioral therapy, genetics, epidemiology and everything in between.

Neuropsychiatry provides concise and clear coverage of topics at the forefront of research, which impact the understanding and management of major neuropsychiatric disorders. Articles take the form of reviews, analysis and original articles which have undergone thorough peer review. The journal is a resource for all physicians and healthcare practitioners who are striving to provide the best possible evidence-based care for their patients also providing a preview of the research and issues on the horizon that are about to transform clinical practice.

Wayne Goodman of the Mount Sinai School of Medicine and Markus Leweke of the Central Institute for Mental Health, Germany are in charge of the editorial direction of Neuropsychiatry, they are supported by a team of international experts making up the editorial advisory board. Wayne Goodman commented “Clinical neuroscience research, fueled by advances in genomics and technological innovations is accelerating at an unprecedented pace. Even the most conscientious consumer of science finds it nearly impossible to keep up to date. This is where Neuropsychiatry fits in: to provide concise and clear coverage of topics at the forefront of research, which impact the understanding and management of major neuropsychiatric disorders.”

Elisa Manzotti, Editorial Director at Future Medicine, said, “The input of all involved in Neuropsychiatry has been invaluable to ensure we have a robust launch in this exciting arena of research and practice.”

Manzotti went on to say, “Neuropsychiatry will comprise topical, concise articles bringing together all disciplines of neuropsychiatry. All submitted articles will be subjected to rigorous peer and constructive peer review by at least three independent referees.”

Selected content from the launch issue can be viewed at www.futuremedicine.com/loi/npy. If you are interested in receiving a free 30-day online trial to evaluate the journals content please contact [email protected], quoting NPYPR11.